Pressure Biosciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.25
- Today's High:
- $0.275
- Open Price:
- $0.275
- 52W Low:
- $0.24
- 52W High:
- $2.2
- Prev. Close:
- $0.28
- Volume:
- 38337
Company Statistics
- Market Cap.:
- $4.44 million
- Book Value:
- -1.282
- Revenue TTM:
- $2.00 million
- Operating Margin TTM:
- -380.79%
- Gross Profit TTM:
- $1.06 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -209.02%
- Return on Equity TTM:
- 0%
Company Profile
Pressure Biosciences Inc had its IPO on 1996-10-31 under the ticker symbol PBIO.
The company operates in the Healthcare sector and Medical Devices industry. Pressure Biosciences Inc has a staff strength of 16 employees.
Stock update
Shares of Pressure Biosciences Inc opened at $0.28 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.25 - $0.28, and closed at $0.25.
This is a -10.71% slip from the previous day's closing price.
A total volume of 38,337 shares were traded at the close of the day’s session.
In the last one week, shares of Pressure Biosciences Inc have slipped by -19.35%.
Pressure Biosciences Inc's Key Ratios
Pressure Biosciences Inc has a market cap of $4.44 million, indicating a price to book ratio of 0 and a price to sales ratio of 9.9474.
In the last 12-months Pressure Biosciences Inc’s revenue was $2.00 million with a gross profit of $1.06 million and an EBITDA of $-7515817. The EBITDA ratio measures Pressure Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Pressure Biosciences Inc’s operating margin was -380.79% while its return on assets stood at -209.02% with a return of equity of 0%.
In Q2, Pressure Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 2.7%.
Pressure Biosciences Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-1.7 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Pressure Biosciences Inc’s profitability.
Pressure Biosciences Inc stock is trading at a EV to sales ratio of 23.1193 and a EV to EBITDA ratio of -5.5122. Its price to sales ratio in the trailing 12-months stood at 9.9474.
Pressure Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.68 million
- Total Liabilities
- $26.54 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Pressure Biosciences Inc ended 2024 with $1.68 million in total assets and $0 in total liabilities. Its intangible assets were valued at $1.68 million while shareholder equity stood at $-25115096.00.
Pressure Biosciences Inc ended 2024 with $0 in deferred long-term liabilities, $26.54 million in other current liabilities, in common stock, $-152230771.00 in retained earnings and $0 in goodwill. Its cash balance stood at $24975.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $163175.00.
Pressure Biosciences Inc’s total current assets stands at $1.05 million while long-term investments were $83883.00 and short-term investments were $0. Its net receivables were $189015.00 compared to accounts payable of $912230.00 and inventory worth $553688.00.
In 2024, Pressure Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Pressure Biosciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.25
- 52-Week High
- $2.2
- 52-Week Low
- $0.24
- Analyst Target Price
- $
Pressure Biosciences Inc stock is currently trading at $0.25 per share. It touched a 52-week high of $2.2 and a 52-week low of $2.2. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.42 and 200-day moving average was $1.06 The short ratio stood at 3 indicating a short percent outstanding of 0%.
Around 93.6% of the company’s stock are held by insiders while 3.6% are held by institutions.
Frequently Asked Questions About Pressure Biosciences Inc
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company’s pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and the Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. The company was incorporated in 1978 and is based in South Easton, Massachusetts.